T
Tomasz Burzykowski
Researcher at University of Hasselt
Publications - 167
Citations - 7888
Tomasz Burzykowski is an academic researcher from University of Hasselt. The author has contributed to research in topics: Surrogate endpoint & Linear model. The author has an hindex of 37, co-authored 157 publications receiving 6626 citations.
Papers
More filters
Journal ArticleDOI
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Tathiane M. Malta,Artem Sokolov,Andrew J. Gentles,Tomasz Burzykowski,Laila M. Poisson,John N. Weinstein,Bozena Kaminska,Joerg Huelsken,Larsson Omberg,Olivier Gevaert,Antonio Colaprico,Patrycja Czerwińska,Sylwia Mazurek,Lopa Mishra,Holger Heyn,Alexander Krasnitz,Andrew K. Godwin,Alexander J. Lazar,Joshua M. Stuart,Katherine A Hoadley,Peter W. Laird,Houtan Noushmehr,Maciej Wiznerowicz +22 more
TL;DR: Novel stemness indices for assessing the degree of oncogenic dedifferentiation are provided and it is found that the dedifferentiated oncogenic phenotype was generally most prominent in metastatic tumors.
Journal ArticleDOI
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis
Gastric (Global Advanced),Xavier Paoletti,Koji Oba,Tomasz Burzykowski,Stefan Michiels,Yasuo Ohashi,Jean-Pierre Pignon,Philippe Rougier,Junichi Sakamoto,Daniel J. Sargent,Mitsuru Sasako,Eric Van Cutsem,Marc Buyse +12 more
TL;DR: Among the RCTs included, postoperative adjuvant chemotherapy based on fluorouracil regimens was associated with reduced risk of death in gastric cancer compared with surgery alone.
Journal ArticleDOI
The validation of surrogate endpoints in meta-analyses of randomized experiments
TL;DR: In this article, the authors proposed a new method for the validation of surrogate endpoints, which leads to the prediction of the effect of treatment upon the true endpoint, given its observed effect upon the surrogate endpoint.
Journal ArticleDOI
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
Marc Buyse,Pierre Thirion,Robert W. Carlson,Tomasz Burzykowski,Geert Molenberghs,Pascal Piedbois +5 more
TL;DR: Analysis of individual data from 3791 patients enrolled in 25 randomised trials of first-line treatment with standard bolus intravenous fluoropyrimidines versus experimental treatments confirms that an increase in tumour response rate translates into a increase in overall survival for patients with advanced colorectal cancer.